文献速递围术期管理与 ERAS急腹症与外科感染

医院价格加成与大型择期手术结局的关联

Hospital Price Markup and Outcomes of Major Elective Operations.
PubMed 文献 · JAMA Surg · 2025-01-01

这项全国横断面研究评估了1960家美国医院在四种大型择期手术中的价格加成比(MR),发现高加成医院(HMH)占194家,其MR中位数为8.5。风险调整后,HMH治疗与主要并发症风险(AOR 1.45)和30天非计划再入院风险(AOR 1.33)显著增加相关。

要点

  • 高加成医院更常见于投资者所有、营利性、位于大都市区的医院。
  • 高加成医院治疗与主要并发症和30天非计划再入院风险增加独立相关。
  • 医院价格加成存在全国性显著差异,高加成医院可能应成为价格监管和透明度政策的优先目标。

核心结论

  • 医院价格加成存在显著差异,高加成医院的质量和价值均较低。

研究设计与样本

  • 全国横断面研究,纳入2022年全国再入院数据库中1960家美国医院,分析18岁及以上接受腹主动脉瘤修复、结肠切除术、冠状动脉旁路移植术和髋关节置换术的患者。

主要发现

  • 1960家医院中194家为高加成医院(HMH),整体医院价格加成比中位数(IQR)为3.0(1.9-4.4)。
  • 仅考虑HMH时,加成比中位数(IQR)为8.5(7.1-10.8);最贵的50家医院加成比中位数为13。
  • 风险调整后,HMH治疗与主要并发症风险增加相关(AOR 1.45;95%CI 1.14-1.84),包括心脏、呼吸、感染和肾脏后遗症风险升高。
  • HMH治疗与30天内非计划再入院风险增加相关(AOR 1.33;95%CI 1.24-1.42)。

临床怎么用

  • 临床医生和医院管理者应关注价格加成与手术质量的关系,高加成可能提示低价值医疗。
  • 政策制定者可优先针对高加成医院推进价格监管、透明度和质量改进。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hospital prices are currently not subject to regulation, yet have profound financial implications for patients, taxpayers, and governments. While significant for the contemporary era of value-based care, US national variation in hospital price markup has not been delineated. OBJECTIVE: To characterize national variation in the hospital price markup for major elective operations and to assess the association of markup with perioperative outcomes and overall quality of care. DESIGN, SETTING, AND PARTICIPANTS: This national cross-sectional study evaluated institutional markup ratios (MRs) across 1960 US hospitals performing 4 major elective operations (abdominal aortic aneurysm repair, colectomy, coronary artery bypass grafting, and hip replacement) among patients aged 18 years and older within the 2022 Nationwide Readmissions Database. MR was defined as the ratio of charges to costs. Centers with MRs in the top decile were considered high-markup hospitals (HMH), with others categorized as non-HMH. Data were analyzed from September 2024 to March 2025. MAIN OUTCOME AND MEASURE: The primary outcome was institutional MR, with secondary consideration of perioperative outcomes. RESULTS: Of 1960 unique institutions, 194 were HMH. The median (IQR) hospital price markup factor was 3.0 (1.9-4.4). Considering only HMH, the median (IQR) MR was 8.5 (7.1-10.8); the top 50 most expensive hospitals marked up the true costs of care by a median factor of 13. On average, HMH were more commonly investor-owned, for-profit hospitals located in metropolitan areas. Of 362 367 patients, 42 620 (11.8%) were treated at HMH. Overall mean (SD) patient age was 65.1 (12.7) years, and 174 067 patients (48.0%) were female. Following risk adjustment, care at HMH was associated with significantly greater odds of major morbidity (adjusted odds ratio [AOR], 1.45; 95% CI, 1.14-1.84), including higher adjusted risk of cardiac, respiratory, infectious, and kidney sequelae. Moreover, treatment at HMH was associated with increased likelihood of nonelective readmission within 30 days (AOR, 1.33; 95% CI, 1.24-1.42). CONCLUSIONS AND RELEVANCE: This cross-sectional study found that considerable variation in price markup exists across hospitals and that HMHs demonstrated both lower quality and value of care. These findings underscore that HMHs represent a key initial target for national policy efforts targeting pricing regulation, transparency, and quality improvement.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Sakowitz S, Bakhtiyar SS, Sanaiha Y, et al. Hospital Price Markup and Outcomes of Major Elective Operations. JAMA Surg. 2025. PMID: 40991249. doi:10.1001/jamasurg.2025.3647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。